A detailed history of Credit Suisse Ag transactions in Immunovant, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 68,119 shares of IMVT stock, worth $1.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,119
Previous 56,056 21.52%
Holding current value
$1.87 Million
Previous $2.36 Million 6.82%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$30.27 - $43.79 $365,147 - $528,238
12,063 Added 21.52%
68,119 $2.2 Million
Q4 2023

Feb 08, 2024

BUY
$31.31 - $44.19 $751 - $1,060
24 Added 0.04%
56,056 $2.36 Million
Q3 2023

Nov 13, 2023

SELL
$18.55 - $39.96 $121,725 - $262,217
-6,562 Reduced 10.48%
56,032 $2.15 Million
Q2 2023

Aug 11, 2023

BUY
$14.2 - $23.75 $173,126 - $289,560
12,192 Added 24.19%
62,594 $1.19 Million
Q1 2023

May 10, 2023

BUY
$15.27 - $19.72 $22,767 - $29,402
1,491 Added 3.05%
50,402 $781,000
Q4 2022

Feb 13, 2023

BUY
$6.59 - $17.75 $56,884 - $153,218
8,632 Added 21.43%
48,911 $868,000
Q3 2022

Nov 10, 2022

BUY
$3.93 - $6.37 $12,835 - $20,804
3,266 Added 8.82%
40,279 $225,000
Q2 2022

Aug 12, 2022

BUY
$3.38 - $5.65 $7,233 - $12,091
2,140 Added 6.14%
37,013 $145,000
Q1 2022

May 16, 2022

BUY
$5.06 - $8.77 $57,749 - $100,092
11,413 Added 48.65%
34,873 $192,000
Q4 2021

Feb 14, 2022

BUY
$7.33 - $9.32 $14,806 - $18,826
2,020 Added 9.42%
23,460 $200,000
Q3 2021

Nov 12, 2021

SELL
$7.01 - $11.37 $330,444 - $535,970
-47,139 Reduced 68.74%
21,440 $186,000
Q2 2021

Aug 16, 2021

BUY
$9.4 - $16.85 $190,509 - $341,498
20,267 Added 41.95%
68,579 $724,000
Q1 2021

May 14, 2021

SELL
$13.08 - $49.6 $226,179 - $857,683
-17,292 Reduced 26.36%
48,312 $775,000
Q4 2020

Feb 12, 2021

BUY
$36.36 - $52.71 $964,194 - $1.4 Million
26,518 Added 67.85%
65,604 $3.03 Million
Q3 2020

Nov 13, 2020

BUY
$22.61 - $38.9 $581,257 - $1 Million
25,708 Added 192.17%
39,086 $1.38 Million
Q2 2020

Aug 12, 2020

BUY
$13.87 - $28.44 $185,552 - $380,470
13,378 New
13,378 $325,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.